Transmedics Group Stock Price, News & Analysis

TransMedics (NASDAQ: TMDX), a medical technology company focused on organ transplant therapy, has granted equity incentives to 14 new employees as employment inducements. The compensation package includes 21,458 non-qualified stock options with an exercise price of $105.24 per share and 14,283 restricted stock units (RSUs).

The stock options will vest 25% after one year, with the remaining vesting monthly over three years. The RSUs will vest 25% annually over four years. Both grants require continued employment and were approved under Nasdaq Listing Rule 5635(c)(4) through the TransMedics Group, Inc. Inducement Plan.

TransMedics (NASDAQ: TMDX), a medical technology company specializing in organ transplant therapy, reported strong Q2 2025 financial results. The company achieved revenue of $157.4 million, marking a 38% increase year-over-year, and generated net income of $34.9 million ($0.92 per diluted share).

Key highlights include receiving conditional IDE approval for the Next-Gen OCS™ Lung trial, launching the NOP ACCESS™ digital ecosystem, and maintaining a strong 61% gross margin. The company has raised its full-year 2025 revenue guidance to $585-605 million, representing 35% growth at the midpoint compared to the previous guidance of $565-585 million.

TransMedics maintains a robust financial position with $400.6 million in cash as of June 30, 2025, and remains focused on achieving its target of 10,000 US NOP transplants by 2028.

TransMedics (NASDAQ: TMDX), a medical technology company specializing in organ transplant therapy solutions, announced its participation in the Canaccord Genuity 45th Annual Growth Conference. The company's management team will deliver a presentation on Tuesday, August 12, 2025, at 11:30 a.m. ET at the InterContinental Boston Hotel.

Investors can access both the live and archived webcast of the fireside chat, along with the company's standard investor presentation, through the "Investors" section of TransMedics' website at investors.transmedics.com.

TransMedics (NASDAQ: TMDX), a medical technology company focused on organ transplant therapy, has scheduled its Second Quarter 2025 financial results announcement for July 30, 2025, after market close.

The company will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results. Investors can join via phone using specific dial-in numbers or access the webcast through TransMedics' investor relations website.

TransMedics Group (NASDAQ: TMDX) announced the granting of inducement awards to 15 new employees on May 21, 2025. The compensation package includes 9,940 non-qualified stock options with an exercise price of $121.31 per share and 6,670 restricted stock units (RSUs). The stock options will vest 25% after one year, with the remaining vesting monthly over three years. The RSUs will vest 25% annually over four years. Both grants are subject to continued employment and were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4) through the TransMedics Group Inducement Plan. The options have a 10-year term.

TransMedics (Nasdaq: TMDX), a medical technology company focused on organ transplant therapy, has announced its participation in two major investor conferences in June 2025. The company will present at the William Blair 45th Annual Growth Stock Conference in Chicago on June 3 at 5:00 p.m. EST and participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami on June 9 at 8:00 a.m. EST. Both presentations will be available via webcast on TransMedics' investor relations website.

TransMedics (NASDAQ: TMDX) reported strong Q1 2025 financial results with total revenue of $143.5 million, up 48% year-over-year. The company achieved a net income of $25.7 million ($0.70 per diluted share) and maintained a robust gross margin of 61%. Growth was primarily driven by increased utilization of their Organ Care System (OCS), particularly in Liver and Heart transplants through the National OCS Program. The company owned 21 aircraft and announced plans for a new design center and manufacturing facility in Italy. Based on strong performance, TransMedics raised its full year 2025 revenue guidance to $565-585 million, representing 30% growth at the midpoint. The company ended Q1 with a strong cash position of $310.1 million.

TransMedics Group (Nasdaq: TMDX), a medical technology company focused on organ transplant therapy, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close.

The company will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on the same day. Investors can participate by dialing (844) 676-6010 (domestic) or (412) 634-6944 (international). A live and archived webcast will be available on the company's investor relations website.

TransMedics Group (TMDX) announced the granting of inducement awards to three new employees on March 28, 2025. The compensation package includes:

• 1,570 non-qualified stock options with an exercise price of $68.58 per share
• 1,043 restricted stock units (RSUs)

The stock options will vest 25% after one year, with the remaining vesting monthly over three years. The RSUs will vest 25% annually over four years. Both grants require continued employment and were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4) through the TransMedics Inducement Plan.